- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04200339
Adolescent SCreening To Help Eliminate Misuse (ASC-THEM)
March 16, 2022 updated by: Sharon Levy, Boston Children's Hospital
The specific aim of this study is to evaluate the performance of three substance use screening instruments (S2BI, BSTAD, and TAPS Tool) against a criterion standard of Diagnostic Statistical Manual - 5 (DSM-5) substance use disorder (SUD) diagnoses in an adolescent population.
Study Overview
Status
Completed
Conditions
Detailed Description
This study seeks to evaluate the psychometric properties of three substance use screening and brief assessment tools for adolescents against criterion standard of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) substance use disorder diagnoses in a population of adolescents who receives care at a participating primary care practice; or, for an initial evaluation at a substance use disorders program for youth.
The three tools to be tested are the Brief Screener for Tobacco, Alcohol and Drugs (BSTAD); Screening to Brief Intervention (S2BI) screening tool; and the Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Tool.
BSTAD and S2BI were developed specifically for use with adolescents and each has been validated in a single trial.
These tools use past-year "frequency of use" questions to determine risk level for a substance use disorder.
The TAPS tool includes both screening and brief assessments and while it has been studied more extensively in adult primary care patients, its validity with adolescents is not known.
For youth, alcohol, marijuana and tobacco use, and particularly early initiation, are associated with greater risk of substance use disorders, use of illicit drugs, misuse of opioids, and opioid use disorders.
Thus, identifying and addressing substance use early is an important form of prevention that can be delivered in medical care settings for this age group.
Study Type
Observational
Enrollment (Actual)
810
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Childrens Hopsital - Adolecents Substance Use and Addiction Program
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Recruitment and study procedures may occur either in-person or remotely.
We will recruit participants to enroll in the study from participating health care sites.
These will include 1) an outpatient adolescent substance use disorders program at a pediatric hospital (ASAP, Boston Children's Hospital), 2) the adolescent medicine program at a federally qualified health center (FQHC) in Boston (Martha Elliot Health Center (MEHC), Boston Children's Hospital), and 3) community-based primary care pediatrics practices that participate in the Pediatric Physicians' Organization at Children's (PPOC).
The FQHC is considered a primary care sites participating in this study.
Description
Inclusion Criteria:
- Be between the ages of 12-17 years, inclusive, at the time of screening.
- A patient registered at one of the primary care sites; or, presenting for an initial substance use disorders evaluation at the youth substance use disorders program site.
- Be willing and able to participate in the study.
Exclusion Criteria:
- Previously enrolled in the current study, as determined by the Chart Review Log/Clinical Staff Referral Log and through self-report of potentially eligible participants.
- Inability to comprehend spoken or written English.
- Inability to self-administer any type of computer tool due to physical limitations.
- Physical or emotional illness that interferes with participation on the day of the appointment, as determined by either the clinical team or research team.
- Per participant self-report, treated in a residential/inpatient substance use disorders treatment program within the past 12 months.
- For patients at primary care sites, current, self-reported enrollment in a substance use disorders treatment program at time of recruitment.
- Per participant self-report, participant is currently in the custody of the Department of Youth Services, the Department of Children and Families, or living with a foster family.
- Per participant self-report, currently pregnant or parenting.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
|---|
|
Adolescents
Adolescents between the ages of 12 and 17 years old (inclusive).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SUD assessment evaluation for performance
Time Frame: single visit
|
The focus of this study is to evaluate the performance of each tool (S2BI, BSTAD, and TAPS Tool) in identifying substance use and substance use disorders at previously identified cut points for alcohol, marijuana and tobacco/nicotine for each tool.
The properties that will be evaluated include sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative likelihood ratio (LR-)
|
single visit
|
|
SUD assessment evaluation for criterion measures
Time Frame: single visit
|
We will examine each substance from each tool against the corresponding substance on the criterion standard measure.
For example, the tobacco item on the BSTAD would be compared to the tobacco item on the WMH CIDI.
|
single visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sharon Levy, MD, MPH, Boston Children's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 21, 2020
Primary Completion (Actual)
February 25, 2022
Study Completion (Actual)
February 25, 2022
Study Registration Dates
First Submitted
December 12, 2019
First Submitted That Met QC Criteria
December 12, 2019
First Posted (Actual)
December 16, 2019
Study Record Updates
Last Update Posted (Actual)
March 18, 2022
Last Update Submitted That Met QC Criteria
March 16, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTN0060-A1
- UG1DA015831 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
This study will comply with the NIH Data Sharing Policy and Implementation Guidance(https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm).
Investigators will also register and report results of the trial in ClinicalTrials.gov,
consistent with the requirements of the Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration (https://grants.nih.gov/policy/clinical-trials/reporting/understanding/nih-policy.htm).
IPD Sharing Time Frame
upon completion
IPD Sharing Access Criteria
Public:
Prior to downloading any study data, the user will be prompted to complete a registration agreement for data use. Users will have to register a name and valid e-mail address in order to download data and to accept their responsibility for using data in accordance with the NIDA Data Share Agreement.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use
-
University of ArkansasNational Center for Advancing Translational Sciences (NCATS)RecruitingParenting | Substance Use Treatment | Perinatal Substance UseUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingAdolescent | Alcohol Use | Mild Alcohol Use Disorder | Mild Substance Use DisorderUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Substance Use Disorder (SUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Active, not recruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorders | Nicotine Use DisorderUnited States
-
Spark Biomedical, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); Baylor College... and other collaboratorsRecruitingSubstance Use Disorders | Alcohol Use Disorder | Alcohol Abuse | Substance Use Disorders Alcohol Use Withdrawal StateUnited States